Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05757076 · ClinicalTrials.gov registry record
Aldosterone Renin Ratio (ARR) Test to Increase Case-detection of Primary Aldosteronism (PA)
A clinical trial, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- 53
- Enrollment target
NCT05757076: Completed study, sponsored by The Cleveland Clinic.
NCT05757076 is a clinical trial that has completed, run by The Cleveland Clinic. The registered enrollment target is 53 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05757076 has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- 53 participants
- Enrollment target
Study Summary
The mission of this project is to increase the detection of Primary Aldosteronism (PA), the most common cause of secondary hypertension, which can either be cured surgically or treated with targeted medications.
Interventions
- PROCEDURE Blood test for ARR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2023-05-02 |
| Est. Completion | 2025-12-29 |
What the finished NCT05757076 record still lists
NCT05757076 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 53 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Blood test for ARR is the first listed.
NCT05757076 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05757076 about?
NCT05757076 is a clinical study titled "Aldosterone Renin Ratio (ARR) Test to Increase Case-detection of Primary Aldosteronism (PA)". The mission of this project is to increase the detection of Primary Aldosteronism (PA), the most common cause of secondary hypertension, which can either be cured surgically or treated with targeted medications.
What is the current status of trial NCT05757076?
This trial is currently completed. The enrollment target is 53 participants. The study started on 2023-05-02. Estimated completion is 2025-12-29.
What interventions are being tested in trial NCT05757076?
The interventions under investigation include: Blood test for ARR (PROCEDURE).
Who is sponsoring clinical trial NCT05757076?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI